Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.

Fonseca, V A; Kelley, D E; Cefalu, W; Baron, M A; Purkayastha, D; Nestler, J E; Hsia, S; Gerich, J E

Fonseca, V A; Kelley, D E; Cefalu, W; Baron, M A; Purkayastha, D; Nestler, J E; Hsia, S; Gerich, J E.

Affiliation

Fonseca VA; Tulane University Medical Center, Endocrinology Department, New Orleans, LA 70112, USA.

Metabolism ; 53(10): 1331-5, 2004 Oct.

Article in En | MEDLINE | ID: mdl-15375790

Subject(s)

Cyclohexanes/therapeutic use; Diabetes Mellitus, Type 2/drug therapy; Glyburide/therapeutic use; Hypoglycemic Agents/therapeutic use; Phenylalanine/therapeutic use; Adult; Aged; Area Under Curve; Blood Glucose/metabolism; Cyclohexanes/adverse effects; Diabetes Mellitus, Type 2/blood; Double-Blind Method; Female; Glucose Clamp Technique; Glyburide/adverse effects; Humans; Hypoglycemic Agents/adverse effects; Insulin/blood; Male; Middle Aged; Nateglinide; Phenylalanine/adverse effects; Phenylalanine/analogs & derivatives

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Phenylalanine / Glyburide / Cyclohexanes / Diabetes Mellitus, Type 2 / Hypoglycemic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Metabolism Year: 2004 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links